At Bienzobas, cancer care is based on the following criteria:
The clinical evidence established in both national and international medical guidelines.
The Bienzobas platform for consultation and verification in relation to adequacy of prescriptions in just 24-48 hours.
The significance of these results for the patient (Value Based Oncology Care).
Regulatory agencies are the official bodies that guarantee the quality, safety, efficacy and provision of correct information in relation to medicines and medical devices for both citizens and health professionals.
The guidelines consist of systematically-developed recommendations that are constantly updated to support both professionals and patients. For the professional, recommendations are based on the best-available scientific evidence; and for the patient, it provides a guarantee that their treatment is based on scrutinised scientific studies.
These are the recommendations from regulatory agencies and the guidelines that Bienzobas regularly applies:
Strict compliance with the approved recommendations by the Regulatory Agencies: in Spain, this is the EMA (European Medicines Agency) and the AEMPS (Spanish Medicines Agency).
NCCN General adherence to the National Comprehensive Cancer Network (NCCN) guidelines. This guideline was compiled by the top 31 hospitals in the USA. It evaluates effectiveness, safety and efficiency.
NICE General adherence to NICE guidelines (National Institute for health and Clinical Excellence, UK). It evaluates effectiveness, safety and cost, i.e. efficiency. Their aim is to ensure the sustainability of the healthcare system whilst maintaining the highest levels of clinical excellence. They take into account the ethical principle of justice, and represent some of the most comprehensive recommendations in the world.
Germany: The IQWIG
United Kingdom: In addition to NICE, there is also the SMC (Scottish Medicines Consortium) and the AWMSG (All Wales Medicines Strategy Group)
Canada: PCODR (pan-Canadian Oncology Drug Review); INESS (Institut National d’Excellence en Santé et en Services Sociaux)
Australia: PBAC (Pharmaceutical Benefits Scheme)
United States: ASCO (American Society of Clinical Oncology); Choosing Wisely, from the ABIM Foundation
European: ESMO (European Society of Medical Oncology); the European Society of Surgical Oncology (ESSO); and the European Society of Radiotherapy and Oncology (ESTRO)
In Spain, management by Bienzobas has made it possible for 92% of processes to be brought in line the medical criteria indicated in the international guidelines.
CONSTANTLY UPDATING
The large numbers of consultation cases and our constant reviewing of updated guidelines allow us to stay abreast of the latest innovations in oncology that will be effective for our patients.
Striking a balance between the effectiveness of treatment and its cost is now one of the main concerns of health managers. The health system is measured by the medical interventions performed (the number of surgeries, for example), and the volume is quantified, but there is no quantification of the results obtained which is where value is really added for patients. When health spending grows without increases in efficiency, its efficiency is decreased or non-existent: this amounts to waste. Creating a system that is sustainable is the future challenge facing healthcare.
In 2006, Michael Porter, an economist and professor at Harvard Business School collaborated with Elisabeth Teisberg, a PhD in Engineering at Stanford, to write the book ‘Redefining HealthCare’ in which they conceived the concept of ‘VALUE BASED HEALTHCARE’. It now serves as the foundational theory for restructuring health systems based on the real value received by the patient, whilst also striving for an improved balance between the financing of services and their real-life effectiveness, i.e. their efficiency.
The cost-effectiveness scale means that not all medicines that are new arrivals on the market, generally associated with a higher cost, will be more effective than cheaper medicines that have proven effectiveness in specific treatments according to medical guidelines. The value to be found in an evidence-based recommendation is to avoid waste, verify prescriptions, and to help make the health system more sustainable.
PATIENTS
Lower costs & better results.
CENTRES
Higher rates of patient satisfaction and improved efficiency of care
INSURERS / ADMINISTRATION
Improved cost management and risk reduction
SOCIETY
Reductions in health spending and improvement of overall health
Bienzobas has an individual approach to treating oncology patients, searching for the best possible treatment option based on the clinical evidence available both nationally and internationally.
However, beyond individual effectiveness, the Bienzobas system also aims to bring resources in oncology to the largest number of cancer patients, offering improvements on a broader scale.
